The role of CtIP (RBBP8) in tamoxifen resistance and human breast cancer
Year: 2007
Type: article
Abstract: Acquired resistance to the antiestrogen tamoxifen constitutes a major clinical \nchallenge in breast cancer therapy. However, the mechanisms involved are still poorly \nunderstood. Therefore, the overall goal and focus of this dissertation are to better \nunderstand the phenomenon of tamoxifen resistance. In preliminary studies, we generated \ntwo independently derived isogenic MCF-7 breast cancer cell line variants (TAMR1 and \nTAMR2) that were resistant to the inhibitory growth effects of tamoxifen. Using serial \nanalysis of gene expression (SAGE), we identified CtIP (CtBP-interacting protein), a \nBRCA1 (Breast cancer 1)- and CtBP (C-terminal binding protein)-interacting protein, as \none of the most significantly down-regulated transcripts in the aforementioned tamoxifen \nresistant cells. We hypothesized that CtIP silencing constitutes a critical event for the \ndevelopment of tamoxifen resistance in breast cancer. We found that silencing \nendogenous CtIP in tamoxifen sensitive cells confers tamoxifen resistance and estrogen \nindependence. On the other hand, re-expression of CtIP in tamoxifen resistant cells \nrestores sensitivity to the inhibitory growth effects of tamoxifen. Importantly, poor \nclinical response to neo-adjuvant endocrine therapy is associated with CtIP deficiency in \nprimary breast carcinomas. Meta-analysis of seven publicly available gene expression \nmicroarray data sets shows that CtIP expression is significantly associated with estrogen \nreceptor (ER), disease free survival and breast cancer metastasis status. Furthermore, we \nfound CtIP protein expression in a majority of ER positive breast cancer cell lines, but \nnone or very little CtIP expression in ER negative lines. These findings indicate that CtIP \nsilencing may be a novel mechanism for the development of tamoxifen resistance in \nbreast cancer, and suggest that CtIP is likely associated with ER function and that CtIP \ngene and protein expression may be useful biomarkers for breast cancer prognosis and \nclinical management. Subsequent studies found a BRCA1-CtIP-CtBP complex in \ntamoxifen sensitive but not resistant cells, whereas BRCA1 is associated with ER in both \ncell lines. We also observed different patterns of occupancy by BRCA1, CtIP and CtBP \non ERE (Estrogen Response Element) region of the pS2 promoter after E2 or tamoxifen \ntreatment. These results support the potential involvement of a BRCA1-CtIP-CtBP \ncomplex in the development of tamoxifen resistance.
Author: Minhao Wu
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W1925428593
